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Bisphenol AF (BPAF) is in the body mainly metabolized to the
corresponding bisphenol AF glucuronide (BPAF-G). While BPAF-G
is not commercially available, enzyme-assisted synthesis of BPAF-G
using the human recombinant enzyme UGT2A1, purification of
BPAF-G by solid phase extraction and semi-preparative HPLC and
chemical characterization of BPAF-G by NMR and LC-MS/MS were
performed and are described here. Furthermore, BPAF glucur-
onidation kinetics with the UGT enzymes that showed the highest
glucuronidation activity in previous studies (i.e hepatic UGTs 1A3,
2B7, and 2B17, intestinal UGT 1A10 and UGT 2A1 that is present in
airways) was performed and data is presented. Hepatic enzymes
exhibited high affinities toward BPAF, while extrahepatic UGTs 2A1
and 1A10 showed the high vmax values (3.3 and 3.0 nmol/min/mg,
respectively). To understand molecular interactions of BPA, BPAF
and BPAF-G with ligand biding sites of several nuclear receptors,
molecular modeling was performed and data on the binding
modes of BPAF, BPA, and BPAF-G in the ligand-binding sites of
nuclear receptors are presented.vier Inc. This is an open access article under the CC BY license
.chemosphere.2018.10.129
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D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎2This article is related to “Endocrine activities and adipogenic
effects of bisphenol AF and its main metabolite” (Skledar et al.,
2019).
& 2018 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications tableubject area Biosynthesis of glucuronides, molecular modeling, glucuronidation kinetics
ore specific
subject areaBiosynthesis of BPAF-G, BPAF glucuronidation kinetics by UGTs 1A3, 2B7, 2B17,
1A10, and 2A1, molecular modeling of BPAF, BPA, and BPAF-G to nuclear
receptorsype of data Table, graph, figure
ow data was
acquiredIn-vitro enzyme-assisted synthesis of BPAF-G using human recombinant
enzyme UGT2A1 as the enzyme source. HPLC-UV analyses was performed
using an Agilent 1100 series HPLC system (Agilent Technologies, Palo Alto, CA,
USA), Varian DirectDrive 800MHz, Bruker AVANCE III 400MHz spectrometer,
LC-MS/MS, Chem3D 16.0 (Chem3D 16.0, ChemOffice Professional 16.0 Suite,
CambridgeSoft, OpenEye Scientific Software, Inc., Santa Fe, NM, USA.ata format Raw and analyzed
xperimental
factorsBPAF-glucuronide was synthesized using the UGT2A1 (0.5mg protein/mL)
as enzyme source and UDPGA (1mM) as cofactor at 37 °C for 24 h.
BPAF glucuronidation kinetics were examined for UGTs 1A3, 2B7, 2B17, 1A10,
and 2A1. Experiments were performed at 8 BPAF concentrations, ranging from
1–50 mM. The incubation times and protein concentrations varied from 10min
to 30min and from 0.01–0.05mg protein/ml, respectively.xperimental
featuresIn-vitro enzyme-assisted synthesis of BPAF-G using human recombinant
enzyme UGT2A1 as the enzyme source; enzyme kinetics of BPAF glucur-
onidation by UGTs 1A3, 2B7, 2B17, 1A10, and 2A1; molecular modeling of BPAF,
BPA and BPAF-G to nuclear receptors.ata source
locationUniversity of Ljubljanaata accessibility Data is available within this article
elated research
articleSkledar DG, Carino A, Trontelj J, Troberg J, Distrutti E, Marchianò S, Tomašič T,
Zega A, Finel M, Fiorucci S et al. Endocrine activities and adipogenic effects of
bisphenol AF and its main metabolite. Chemosphere. 2019 215:870-880 [1]Value of the data
 The data show the optimized In-vitro enzyme-assisted synthesis of BPAF-G using the human
recombinant enzyme UGT2A1 as the enzyme source.
 The data of enzyme kinetics show very high affinities of hepatic UGTs 2B7 and 2B17.
 The data show binding modes of BPA, BPAF and BPAF-G in the ligand-binding sites of different
nuclear receptors
 The data will be important for better understanding of differences in endocrine activities among
the tested compounds that were observed in previous in vitro and in vivo studies.
 These data will be important for better understanding of biotransformation and elimination
of BPAF.et al., Data on biosynthesis of BPAF glucuronide, enzyme
molecular modeling, Data in Brief (2018), https://doi.org/
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The present data provide enzyme kinetics curves and obtained kinetics parameters for BPAF
glucuronidation by UGTs 1A3, 1A10, 2A1, 2B7, and 2B17 (Fig. 1, Table 1). While BPAF-G is not com-
mercially available, enzyme-assisted synthesis of BPAF-G using the human recombinant enzymeTable 1
Kinetic parameters for BPAF glucuronidation by UGTs 1A3, 1A10, 2A1, 2B7, and 2B17.
Enzyme Model Vmax (nmol/min/mg) Km (lM) r2 Ksi
2A1 MM 3.3 7 0.1 8.4 7 0.8 0.98
1A10 SI 3.0 7 0.4 187 3 0.99 35 7 8
2B7 SI 0.21 7 0.01 0.9 7 0.1 0.96 27 7 3
2B17 SI 0.337 0.01 1.17 0.1 0.98 123 7 25
1A3 SI 0.79 7 0.17 22 7 6 0.98 8.0 7 2.1
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Fig. 1. Enzyme kinetics of BPAF glucuronidation by UGTs 1A3, 1A10, 2A1, 2B7, and 2B17.
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D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎4UGT2A1 was performed. Structural characterization of biosynthesized BPAF-G was performed by
NMR and LC-MS/MS. Data presented 1H NMR and 2D TOCSY spectra of BPAF-G (Fig. 2) as well as
representative LC-MS/MS chromatograms (Fig. 3). BPA, BPAF and BPAF-G showed agonistic and/or
antagonistic activities toward some of the nuclear receptors [1]. The binding modes of the active
bisphenols in the ligand-binding sites of these nuclear receptors as agonist-bound and antagonist-
bound conformations at the molecular level were investigated using molecular docking and the data
is presented here (Table 2, Fig. 4). For the androgen and thyroid receptors, and for PXR and PPARγ, the
only crystal structures available were in complex with agonists, and therefore docking of the ligands
to the potential antagonist-bound conformations of these receptors could not be performed.
Bisphenol A and BPAF mimicked the binding mode of E2 in the ligand binding site of ER (Fig. 4A).
The lipophilic central core of BPA and BPAF overlaps with the steroid core of the natural ligand, while
the hydroxyl groups provide sites for additional hydrogen bond formation, which supports the
observed agonistic activities of BPA and BPAF toward ER. The higher Chemgauss4 scoring function
score for BPAF (-13.48) compared to BPA (-12.76) also corresponds to the observed differences in their
in-vitro activities toward hERα, and is due to the more extensive hydrophobic interaction network of
BPAF. As the agonist-bound ER is in a closed conformation, BPAF-G is too bulky to fit the binding site,
which supports its lack of agonistic activity. In the antagonist-bound conformation of ER, the ligand
binding site is larger, and there is enough space to accommodate all three of these bisphenols;
however, they might not provide enough steric bulk, such as provided by tamoxifen, to prevent the
conformational changes of ER that are necessary for its activation. In the case of the androgen, thyroid
and glucocorticoid receptors, BPA and BPAF, but not BPAF-G, are predicted here to bind to the
dihydrotestosterone-, T3-, and cortisol-binding sites, respectively. However, in comparison with the
natural agonists, they appear not to offer enough steric and/or binding-interaction complementarity
with the binding site to result in receptor activation. In contrast, BPA and BPAF show antagonistic
activities against these three receptors. Among these, only the antagonist-bound conformation of the
glucocorticoid receptor is available. Comparisons of mifepristone with BPA and BPAF in terms of their
predicted binding modes (Fig. 4B) show that these bisphenols partially occupy the binding site to
potentially prevent cortisol binding. However, BPA and BPAF do not form as many interactions
(i.e., hydrogen bonds, hydrophobic interactions) as the potent antagonist mifepristone. The PXR
(Fig. 4C), FXR (Fig. 4D, E) and PPARγ ligand-binding sites provide enough space for the binding of BPA,
BPAF, and BPAF-G. As similar orientations and interactions were predicted for all three of these
bisphenols, we cannot rationalise the observed differences in their activities based on these docking
calculations.ig. 2. 1H NMR and 2D TOCSY spectra were recorded at 25 °C on a Varian DirectDrive 800MHz spectrometer equipped with a
ryoprobe, in DMSO-d6 solution with TMS as an internal standard. 2D COSY spectra were recorded on a Bruker AVANCE III 400
Hz spectrometer in DMSO-d6solution, with TMS as internal standard. Data processing was performed with the MestReNova
oftware. The 1H resonances were assigned based on characteristic chemical shifts and signal multiplicity of 1D proton spectra
nd 1H-1H correlations in 2D COSYand TOCSY. 1H NMR (800MHz, DMSO-d6) δ 9.94 (s, 1H, H-7), 7.23 (d, J ¼ 8.5 Hz, 2H, H-10,14),
.12 (d, J ¼ 8.4 Hz, 2H, H-4,6), 7.09 (d, J ¼ 8.9 Hz, 2H, H-11,13), 6.83 (d, J ¼ 8.5 Hz, 2H, H-1,3), 5.26 (d, J ¼ 4.8 Hz, 1H, H-27), 5.02
s, 1 H, H-26), 4.91 (d, J ¼ 7.6 Hz, 1H, H-16), 3.47-3.40 (m, 1H, H-20), 3.28-3.18 (m, 2H, H-17,18), 3.17-3.12 (m, 1H, H-19).
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Fig. 2. (continued)
Please cite this article as: D.G. Skledar, et al., Data on biosynthesis of BPAF glucuronide, enzyme
kinetics of BPAF glucuronidation, and molecular modeling, Data in Brief (2018), https://doi.org/
10.1016/j.dib.2018.12.033i
D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 5
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
Fig. 3. Chromatograms for LC-MS/MS characterization of BPAF-G. Top:Negative ion full-scan analysis of the purified pooled
BPAF-G fraction and its corresponding MS spectrum (middle). Bottom: Product ion scan from precursor ion m/z 511 reveals all
of the characteristic fragments of glucuronide (m/z 113, 175) and of BPAF (m/z 335, 265).
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2.1. Enzyme kinetics of BPAF glucuronidation by UGTs 1A3, 1A10, 2A1, 2B7, and 2B17
Glucuronidation activities of BPAF were tested in the recombinant human UGTs 1A3, 1A10, 2A1,
2B7, and 2B17. Selected experimental conditions are collected in Table 3. Briefly, the incubation
mixtures contained phosphate buffer (50mM, pH 7.4), MgCl2 (10mM), 2% DMSO, BPAF at 8 different
concentrations (1–50 mM) and UGT enzyme (Table 3) and were initiated by addition of UDPGA at the
final concentration of 5mM. Samples were incubated from 10–30min at 37 °C and the reactions were
terminated by the addition of 10 mL 70% perchloric acid and transferred to ice for 15min. The tubes
were then centrifuged at 16,000 g for 10min and the supernatants were subjected to HPLC analysis.
The HPLC analysis was performed as described previously [1].
The data were analyzed using the GraphPad Prism 5.04 software for Windows (GraphPad Software
Inc., San Diego, CA, USA), with the most appropriate kinetics model selected (i.e., Michaelis–Menten
or substrate inhibition), as follows:
MichaelisMenten: v¼ Vmax S½ 
Kmþ S½ 
ð1ÞPlease cite this article as: D.G. Skledar, et al., Data on biosynthesis of BPAF glucuronide, enzyme
kinetics of BPAF glucuronidation, and molecular modeling, Data in Brief (2018), https://doi.org/
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Table 2
Selected crystal structures of nuclear receptors used in molecular modeling studies.
Receptor Bound ligand PDB code Reference
Estrogen Estradiola 1A52 [2]
4-Hydroxytamoxifenb 2JF9 [3]
Androgen Dihydrotestosterone a 3L3X [4]
Thyroid Triiodothyroninea 3GWS [5]
Glucocorticoid Cortisola 4P6X [6]
Mifepristoneb 3H52 [7]
PXR 17α-Ethinylestradiola 41F [8]
FXR MFA-1a 3BEJ [9]
N-Benzyl-N-(3-(tert-butyl)-4-hydro-
xyphenyl)-2,6-dichloro-4-(dimethyla-
mino) Benzamideb
4OIV [10]
PPARγ Tetrachlorobisphenol Aa 3OSI [11]
a agonist;
b antagonist
D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 7Substrateinhibition: v¼ Vmax S½ 
Kmþ S½  1þ S½ Ksi
  ð2Þ
(v, velocity of the reaction; vmax, maximal enzyme velocity; S, substrate concentration; Km,
Michaelis–Menten constant; Ksi, constant of substrate inhibition).
2.2. Biosynthesis of bisphenol AF glucuronide
BPAF-glucuronide is not commercially available, and therefore we performed enzyme-assisted
synthesis using the human recombinant enzyme UGT2A1 as the enzyme source. The incubation
mixture had a final volume of 200mL, and contained 50mM phosphate buffer, pH 7.4, 10mM MgCl2,
UGT2A1 at a final concentration of 0.5mg protein/mL, and the 0.1% bovine serum albumin (fatty acid
free). BPAF was dissolved in DMSO and added in two equal aliquots (at the beginning, after 8 h) to a
final concentration of 0.5mM. The reaction mixture was preincubated for 5min at 37 °C, and then the
glucuronidation reaction was initiated by addition of UDPGA to a final concentration of 1mM. The
glucuronidation reaction was carried out for 24 h at 37 °C, and then terminated by addition of ice-cold
25% (v/v) acetonitrile, and transfer to 20 °C for 48 h. Following this, the mixture was centrifuged at
16,000 g for 10min. The supernatant was collected, and subjected to solid phase extraction for
cleaning and concentration of the samples. The aqueous phases of the incubation mixtures were
loaded to the pre-conditioned (6mL methanol, 6mL water) cartridges. Each cartridge was then
washed with 6mL water and dried under vacuum. Elution was performed with 10mL methanol. The
methanol was evaporated under reduced pressure, and the solid residue was reconstituted in 20mL
20% acetonitrile and subjected to semi-preparative HPLC. The glucuronide fractions were pooled, the
acetonitrile was removed under reduced pressure, and the water was removed by lyophilisation. The
resulting BPAF-G was characterized using both LC-MS/MS and 1H-nuclear magnetic resonance (NMR).
2.3. Molecular modeling of BPAF, BPA and BPAF-glucuronide, ligand and protein preparation, and ligand
docking
Three-dimensional models of BPA, BPAF and BPAF-G were built usingChem3D 16.0 (Chem3D 16.0,
ChemOffice Professional 16.0 Suite, CambridgeSoft). The geometries and charges of the molecules
were optimized using the MMFF94 force-field, and partial atomic charges were assigned in Chem3D
16.0 [12]. The energy was minimized until the gradient value was smaller than 0.001 kcal / (molA°).
The optimized structure was further refined with the GAMESS interface in Chem3D 16.0 (ChemOffice
Professional 16.0 Suite, CambridgeSoft), using the semi-empirical PM3 method, the QA optimizationPlease cite this article as: D.G. Skledar, et al., Data on biosynthesis of BPAF glucuronide, enzyme
kinetics of BPAF glucuronidation, and molecular modeling, Data in Brief (2018), https://doi.org/
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Fig. 4. Docking binding mode of X-ray ligands (Table 2, yellow), BPA (green) and BPAF (magenta) in the ligandbinding sites of
the estrogen receptor (a)(agonist-bound conformation; gray), glucocorticoid receptor (b)(antagonist-bound conformation;
cyan), PXR (c)(agonist-bound conformation; orange), FXR (d)(agonist-bound conformation; green), and FXR (e)(antagonist-
bound conformation; brown). The ligand is shown as a stick model, colored according to the atom types (blue, N; red, O;
orange, S; green, Cl). For clarity, only the protein amino acids that form hydrogen bonds with the ligands are shown as sticks.
Hydrogen bonds are indicated by black dotted lines.
D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎8algorithm, and GasteigerHückel charges for all of the atoms, for 100 steps. A library of conformers of
BPA, BPAF and BPAF-G was generated using the OMEGA software (release 2.5.1.4, OpenEye Scientific
Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) using the default settings, which resulted in a
maximum of 200 conformers per ligand [13].
For docking with the FRED software (Release 3.2.0.2, OpenEye Scientific Software, Inc., Santa Fe,
NM, USA; www.eyesopen.com), the proteins (Table 2) were prepared using MAKE RECEPTOR (Release
3.2.0.2, OpenEye Scientific Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) [14–16]. The grid
box around the ligand bound in the crystal structure was generated automatically and was notPlease cite this article as: D.G. Skledar, et al., Data on biosynthesis of BPAF glucuronide, enzyme
kinetics of BPAF glucuronidation, and molecular modeling, Data in Brief (2018), https://doi.org/
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Table 3
Experimental conditions for measuring BPAF glucuronidation kinetics.
Enzyme Substrate concentra-
tions (lM)
Enzyme concentra-
tion (mg/mL)
Incubation
times (min)
UGT1A3 1, 2.5, 5, 10, 20, 30, 40,
50
0.01 20
UGT1A10 0.25, 1, 2.5, 5, 10, 15, 20,
30, 40, 50
0.01 10
UGT2A1 1, 2.5, 5, 10, 20, 30, 40,
50
0.01 10
UGT2B7 0.25, 1, 1.5, 2.5, 5, 10, 20,
30, 40
0.05 30
UGT2B17 0.1, 0.5, 1, 2.5, 5, 10, 20,
30, 40, 50
0.01 10
D.G. Skledar et al. / Data in Brief ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 9adjusted, which resulted in different grid box sizes depending on the bound ligand. For ‘Cavity
detection’, the slow and effective ‘Molecular’ method was used for the detection of binding sites. The
inner and outer contours of the grid box were also calculated automatically using the ‘Balanced’
settings for the ‘Site shape potential’ calculation, which again resulted in different outer contour sizes
that depended on the bound ligand. The inner contours were disabled and no constraints were used
for the docking calculations.
Bisphenol A, BPAF and BPAF-G were docked using FRED (Release 3.2.0.2. OpenEye Scientific
Software, Inc., Santa Fe, NM, USA; www.eyesopen.com) [14–16]. The docking resolution was set to
high, with the other settings set as the defaults. Ten docking solutions were inspected visually, and
the best-ranked FRED-calculated conformation was used for analysis and representation.Acknowledgments
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